secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2026-11-02T12:15:22+00:00
Accession:  0001104659-26-120915
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

FDA accepts uniQure's Huntington's gene therapy BLA, grants Priority Review with PDUFA date May 1, 2027
--------------------------------------------------------------------------------

- FDA accepted for review the BLA for ifezuntirgene inilparvovec (AMT-130) under the Accelerated Approval pathway with Priority Review; PDUFA target action date May 1, 2027.
- In its acceptance letter, FDA said it is tentatively planning to discuss the application at an Advisory Committee meeting; date and timelines not yet finalized.
- Confirmatory study aligned with FDA: ~200 patients randomized 2:1 to ifezuntirgene inilparvovec vs standard of care, Total Functional Capacity primary endpoint at 36 months.
- BLA rests on 36-month Phase I/II data vs a propensity score-matched external control from the Enroll-HD database, disclosed Sept 24, 2025; 51 patients dosed in the program.
- First Huntington's therapy with Breakthrough Therapy and RMAT designations; also holds Fast Track. US confirmatory-trial screening planned by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/0001104659-26-120915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-120915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer